This quarterly industry report by Lyfegen provides an in-depth analysis of the public drug access and pricing agreements landscape across major global regions. Drawing from the extensive Lyfegen Library, which includes over 5,500 public agreements, the report offers valuable insights and updates relevant to health insurances, governments, hospital payers, consultants, and pharmaceutical companies.
Comprehensive Regional Analyses
Asia
Detailed examination of drug reimbursement processes in China, Japan, and South Korea, including the roles of various regulatory bodies and opportunities in commercial health insurance.
Europe
Insights into the healthcare systems of Germany, Spain, and Portugal, with a focus on the mechanisms of drug evaluations, pricing negotiations, and the implementation of innovative pricing models.
Trending and Innovative Agreements
Overview of trending agreements in each region, reflecting global strategies and practices in healthcare rebate management.
Introduction of new features in Lyfegen’s platform, such as the Mechanism of Action (MoA) for a deeper understanding of drug mechanisms and Featured Agreements for curated global insights.
Theme-Specific Research
Research focused on Alzheimer’s, Dementia, and Cystic Fibrosis, highlighting evolving reimbursement models and strategic approaches to managing treatment costs and patient access.
Key Industry Trends
Emerging trends in reimbursement agreements, such as outcome guarantees, restricted coverage, and price-volume agreements, demonstrating a shift towards innovative strategies to improve patient outcomes and manage healthcare expenditures.
Dear Readers,
As we present our latest quarterly industry report, I want to share some thoughts on what these findings mean for us at Lyfegen
This report, grounded in thorough research and analysis, offers an overview of significant trends and strategies in healthcare rebate management across key global regions. Our focus spans from Europe to spotlight regions like APAC. Each region has its unique challenges and solutions, and understanding these nuances is crucial for our work.
We have also updated our Lyfegen platform, continuously improving to meet the needs of a changing industry. This report details these updates, the current models we are using, and the impact we anticipate they will have.
Moreover, the report dives into emerging trends and specific themes within the healthcare sector, offering a comprehensive view of the landscape we operate in. This includes an analysis based on trending agreements, which I believe is especially valuable for strategic planning.
I want to thank everyone who contributed to this report. Your hard work and dedication are what make Lyfegen a leader in our field. I also want to express my gratitude to our customers and partners for their ongoing support and collaboration.
We’re excited about what the rest of 2024 has in store, as we use these insights to continue bridging the gap to smarter and faster access to medicines for patients.
Girisha Fernando
CEO & Founder
* By sending this message, you agree to our privacy policy.
Sign up & be the first to know about INNOVATIONS
* By sending this message, you agree to our privacy policy.
